methylene blue has been researched along with Congenital Zika Syndrome in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
Butler, D; D'Brant, L; Hu, S; Huang, R; Koetzner, CA; Kramer, LD; Kuo, L; Lang, Y; Li, H; Li, Z; Rugenstein, N; Sakamuru, S; Samrat, S; Tharappel, A; Trudeau, N; Xia, M; Zhang, J | 1 |
2 other study(ies) available for methylene blue and Congenital Zika Syndrome
Article | Year |
---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Methylene blue is a potent and broad-spectrum inhibitor against Zika virus
Topics: A549 Cells; Administration, Oral; Animals; Antiviral Agents; Cell Line; Dengue Virus; Disease Models, Animal; Gene Expression Regulation, Viral; Humans; Male; Methylene Blue; Mice; Protease Inhibitors; Protein Binding; RNA Helicases; Serine Endopeptidases; Viral Load; Viral Nonstructural Proteins; Viral Proteins; Virus Internalization; Zika Virus; Zika Virus Infection | 2020 |